Acrux Limited (ARUXF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Acrux Limited (ARUXF) with AI Score 46/100 (Weak). Acrux Limited develops and commercializes generic and topical pharmaceuticals, focusing on hormone therapies. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Acrux Limited (ARUXF) Healthcare & Pipeline Overview
Acrux Limited is an Australian biotechnology company specializing in the development and commercialization of topical and generic pharmaceuticals, primarily hormone therapies. With a focus on testosterone and estradiol products, Acrux serves international markets, facing competition in the generic drug landscape while maintaining a negative profit margin.
Investment Thesis
Acrux Limited presents a challenging investment thesis due to its negative profit margin of -83.8% and a P/E ratio of -2.09. The company's focus on generic and topical pharmaceuticals, particularly hormone therapies, offers potential in a market with consistent demand. Key value drivers include successful commercialization of existing products like Evamist and Lenzetto, as well as the development and launch of new testosterone solutions. Growth catalysts involve expanding into new geographic markets and securing regulatory approvals for novel formulations. However, potential risks include intense competition in the generic drug market, regulatory hurdles, and the company's current financial instability. Investors should closely monitor Acrux's ability to improve profitability and generate sustainable revenue growth.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.00B indicates a small capitalization company, potentially leading to higher volatility.
- P/E Ratio of -2.09 reflects the company's current lack of profitability.
- Profit Margin of -83.8% signifies significant losses and operational inefficiencies.
- Gross Margin of 56.9% suggests potential for profitability if operational costs are managed effectively.
- Beta of 0.91 indicates the stock's price is slightly less volatile than the market.
Competitors & Peers
Strengths
- Specialization in topical drug formulations.
- Established presence in the hormone therapy market.
- International distribution network.
- Expertise in developing generic pharmaceuticals.
Weaknesses
- Negative profit margin.
- High dependence on a limited number of products.
- Small market capitalization.
- Limited financial resources for R&D and marketing.
Catalysts
- Upcoming: Regulatory approvals for new testosterone formulations in key markets could drive revenue growth.
- Ongoing: Expansion of distribution partnerships in emerging markets to increase market reach.
- Ongoing: Development and launch of innovative drug delivery systems to enhance product differentiation.
Risks
- Potential: Intense competition from generic drug manufacturers could erode market share and pricing power.
- Potential: Stringent regulatory requirements and potential delays in approvals could hinder product launches.
- Ongoing: Negative profit margin and limited financial resources pose a risk to the company's long-term viability.
Growth Opportunities
- Expansion into Emerging Markets: Acrux can pursue growth by expanding its geographic presence into emerging markets in Asia and Latin America. These regions have a growing middle class and increasing healthcare expenditure, creating opportunities for hormone therapies. Successful market entry could significantly boost revenue within the next 3-5 years, requiring strategic partnerships and regulatory approvals.
- Development of Novel Drug Delivery Systems: Investing in research and development to create innovative drug delivery systems for hormone therapies can provide a competitive edge. This includes developing transdermal patches or subcutaneous injections with improved efficacy and patient compliance. Successful innovation could lead to patent protection and increased market share within 2-4 years.
- Strategic Partnerships and Acquisitions: Acrux can pursue strategic partnerships with larger pharmaceutical companies to leverage their distribution networks and marketing capabilities. Acquisitions of smaller companies with complementary product portfolios can also expand Acrux's market reach and product offerings. These initiatives could yield significant revenue growth within 1-3 years.
- Focus on Personalized Medicine: Tailoring hormone therapies to individual patient needs based on genetic and physiological factors can improve treatment outcomes and patient satisfaction. This approach requires investment in diagnostic tools and data analytics to personalize treatment regimens. The personalized medicine market is growing rapidly, offering long-term growth potential for Acrux.
- Increased Investment in Marketing and Sales: Enhancing marketing and sales efforts to increase awareness and adoption of Acrux's products can drive revenue growth. This includes targeted advertising campaigns, physician education programs, and direct-to-consumer marketing. Effective marketing strategies can lead to increased sales and market share within 1-2 years.
Opportunities
- Expansion into emerging markets.
- Development of novel drug delivery systems.
- Strategic partnerships and acquisitions.
- Focus on personalized medicine.
Threats
- Intense competition from generic drug manufacturers.
- Stringent regulatory requirements.
- Patent expirations.
- Economic downturns affecting healthcare spending.
Competitive Advantages
- Proprietary topical drug formulations.
- Established presence in hormone therapy market.
- International distribution network.
- Expertise in developing generic pharmaceuticals.
About ARUXF
Acrux Limited, founded in 1998 and based in West Melbourne, Australia, is a pharmaceutical company focused on developing and commercializing generic and topical pharmaceuticals. The company's primary focus is on hormone therapies, including treatments for low testosterone in men and menopausal symptoms in women. Acrux offers a range of testosterone solutions, including oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels. These products aim to address the needs of adult males experiencing low or no testosterone. Additionally, Acrux provides estradiol sprays under the Evamist and Lenzetto brand names, designed to alleviate flushes associated with menopause in women. Acrux operates in Australia, Europe, the United States, and other international markets, distributing its products through partnerships and direct sales channels. The company competes with other pharmaceutical companies in the generic and branded hormone therapy markets, striving to innovate and expand its product portfolio while navigating regulatory landscapes and market dynamics. Acrux's strategy involves developing differentiated formulations and delivery systems to enhance patient outcomes and market share.
What They Do
- Develops and commercializes generic pharmaceuticals.
- Specializes in topical drug formulations.
- Offers testosterone solutions for men with low testosterone.
- Provides estradiol sprays for women experiencing menopausal symptoms.
- Markets products in Australia, Europe, the United States, and internationally.
- Focuses on hormone replacement therapies.
- Utilizes various drug delivery methods, including tablets, gels, and patches.
Business Model
- Develops and manufactures generic and topical pharmaceuticals.
- Commercializes products through partnerships and direct sales.
- Generates revenue from the sale of testosterone and estradiol products.
- Focuses on international markets, including Australia, Europe, and the United States.
Industry Context
Acrux Limited operates within the biotechnology industry, specifically focusing on generic and topical pharmaceuticals. The market for hormone therapies, including testosterone and estradiol products, is driven by an aging population and increasing awareness of hormonal imbalances. The industry is characterized by intense competition from both generic and branded drug manufacturers. Companies like Acrux must navigate stringent regulatory requirements and evolving market dynamics to maintain and grow their market share. The global hormone replacement therapy market is expected to grow, driven by advancements in drug delivery systems and increasing patient demand.
Key Customers
- Adult males with low or no testosterone.
- Women experiencing menopausal symptoms.
- Pharmacies and distributors in various countries.
- Healthcare providers prescribing hormone therapies.
Financials
Chart & Info
Acrux Limited (ARUXF) stock price: Price data unavailable
Latest News
No recent news available for ARUXF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARUXF.
Price Targets
Wall Street price target analysis for ARUXF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ARUXF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: John Warmbrunn
CEO
John Warmbrunn serves as the CEO of Acrux Limited. His background includes extensive experience in the pharmaceutical industry, with a focus on commercialization and strategic development. Prior to joining Acrux, Warmbrunn held leadership positions at various pharmaceutical companies, where he was responsible for driving revenue growth and expanding market share. His expertise spans across product development, regulatory affairs, and international market expansion. Warmbrunn's experience positions him to lead Acrux in navigating the competitive pharmaceutical landscape.
Track Record: Under John Warmbrunn's leadership, Acrux has focused on expanding its international presence and developing new drug delivery systems. Key achievements include securing regulatory approvals for its products in new markets and forging strategic partnerships to enhance distribution. Warmbrunn has also overseen efforts to improve operational efficiency and reduce costs, although the company continues to face profitability challenges.
ARUXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acrux Limited may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to stocks listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, bankrupt entities, or companies with questionable operations.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume can lead to price volatility and difficulty in buying or selling shares.
- OTC Other listing indicates the company may not meet minimum financial standards.
- Potential for fraud or manipulation is higher in OTC markets.
- Lack of regulatory oversight compared to major exchanges.
- Verify the company's registration and legal status.
- Review available financial statements and assess the company's financial health.
- Research the background and experience of the company's management team.
- Evaluate the company's business model and competitive landscape.
- Assess the company's compliance with regulatory requirements.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established presence in the pharmaceutical industry.
- International distribution network.
- Focus on developing generic pharmaceuticals.
- Development of topical drug formulations.
ARUXF Healthcare Stock FAQ
What does Acrux Limited do?
Acrux Limited is a pharmaceutical company that develops and commercializes generic and topical pharmaceuticals, with a primary focus on hormone therapies. The company offers testosterone solutions for men with low testosterone and estradiol sprays for women experiencing menopausal symptoms. Acrux operates in Australia, Europe, the United States, and other international markets, distributing its products through partnerships and direct sales channels. The company aims to provide effective and convenient hormone replacement therapies to improve patient outcomes.
What do analysts say about ARUXF stock?
Analyst coverage of ARUXF is limited due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio and profit margin, reflect the company's current financial challenges. Growth considerations include the successful commercialization of existing products and the development of new formulations. Investors should conduct thorough due diligence and consider the risks associated with investing in OTC stocks before making any investment decisions. There is no consensus rating available.
What are the main risks for ARUXF?
The main risks for Acrux Limited include intense competition from generic drug manufacturers, stringent regulatory requirements, and its negative profit margin. The company's reliance on a limited number of products also poses a risk, as any setbacks in product development or commercialization could significantly impact revenue. Additionally, the OTC listing increases the risk due to limited financial disclosure and potential price volatility. Investors should carefully consider these risks before investing in ARUXF.
What are the key factors to evaluate for ARUXF?
Acrux Limited (ARUXF) currently holds an AI score of 46/100, indicating low score. Key strength: Specialization in topical drug formulations.. Primary risk to monitor: Potential: Intense competition from generic drug manufacturers could erode market share and pricing power.. This is not financial advice.
How frequently does ARUXF data refresh on this page?
ARUXF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ARUXF's recent stock price performance?
Recent price movement in Acrux Limited (ARUXF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialization in topical drug formulations.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ARUXF overvalued or undervalued right now?
Determining whether Acrux Limited (ARUXF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ARUXF?
Before investing in Acrux Limited (ARUXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage and financial data for ARUXF.
- OTC listing increases investment risk.